Metastatic Esophageal Squamous Cell Carcinoma Clinical Trial
Official title:
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma
The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
There will be 2 parts to the study: the cisplatin and 5-fluorouracil (5-FU) (FP) and paclitaxel and cisplatin (TP) Safety Run-in (Part 1) and the Main Study (Part 2). In Part 1 (FP and TP Safety Run-in), participants will be treated with pembrolizumab plus lenvatinib plus FP or TP. Dose-limiting toxicities, safety, and tolerability will be assessed. In Part 2 (Main Study), participants (not including those participating in Part 1) will be treated with pembrolizumab plus lenvatinib plus chemotherapy or pembrolizumab plus chemotherapy. Efficacy, safety, and tolerability will be assessed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01142388 -
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
| Recruiting |
NCT06138028 -
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05512520 -
Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）
|
Phase 2 | |
| Active, not recruiting |
NCT05142709 -
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
|
||
| Completed |
NCT06190652 -
Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
|
||
| Not yet recruiting |
NCT05522894 -
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
|
Phase 2 | |
| Completed |
NCT01472419 -
Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma
|
N/A | |
| Enrolling by invitation |
NCT03800953 -
The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06265285 -
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
|
Phase 2 | |
| Recruiting |
NCT05978193 -
Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05760391 -
A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.
|
N/A | |
| Active, not recruiting |
NCT04460937 -
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
|
Phase 1 |